Why the study?
Does Nafamostat mesilate promote endothelium-dependent vasorelaxation via the Akt-eNOS pathway in HUVECs and rat aorta tissues?
Does Nafamostat mesilate promote endothelium-dependent vasorelaxation via the Akt-eNOS pathway in HUVECs and rat aorta tissues?
Nafamostat mesilate promotes endothelium-dependent vasorelaxation by increasing nitric oxide generation via the Akt/eNOS signaling pathway.
Supports mechanistic research on nafamostat mesilate; leaves open clinical translation pending human studies.
Nafamostat mesilate (NM), a synthetic serine protease inhibitor, has anticoagulant and anti-inflammatory properties. The intracellular mediator and external anti-inflammatory external signal in the vascular wall have been reported to protect endothelial cells, in part due to nitric oxide (NO) production. This study was designed to examine whether NM exhibit endothelium dependent vascular relaxation through Akt/endothelial nitric oxide synthase (eNOS) activation and generation of NO. NM enhanced Akt/eNOS phosphorylation and NO production in a dose- and time-dependent manner in human umbilical vein endothelial cells (HUVECs) and aorta tissues obtained from rats treated with various concentrations of NM. NM concomitantly decreased arginase activity, which could increase the available arginine substrate for NO production. Moreover, we investigated whether NM increased NO bioavailability and decreased aortic relaxation response to an eNOS inhibitor in the aorta. These results suggest that NM increases NO generation via the Akt/eNOS signaling pathway, leading to endothelium-dependent vascular relaxation. Therefore, the vasorelaxing action of NM may contribute to the regulation of cardiovascular function.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: